|Day Low/High||89.49 / 91.50|
|52 Wk Low/High||58.59 / 96.95|
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Applications to be accepted through Friday, April 12 at 11:59 p.m. EDT
Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.
Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.
Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.
Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.
News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
U.S. stocks look set for a mixed open Thursday, amid the busiest reporting session of the earnings season, even as global markets extend gains after the Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.
Many see the Fed as done for the year. Never assume. Read the words as they are written.
Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.
Global stocks extended gains Thursday, with markets in Asia rising to the highest level in four months, after the U.S. Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.
Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
Big pharma is shaping up to be a consolidating category in 2019.
Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.
NEW YORK, Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: MINDBODY, Inc.
My stated reason for being in Pfizer all along has been price stability and income.
I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.
This is the kind of reversal that happens in a bull market.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.